1
|
Arditi C, Eicher M, Colomer‐Lahiguera S, Bienvenu C, Anchisi S, Betticher D, Dietrich P, Duchosal M, Peters S, Peytremann‐Bridevaux I. Patients' experiences with cancer care in Switzerland: Results of a multicentre cross-sectional survey. Eur J Cancer Care (Engl) 2022; 31:e13705. [PMID: 36130722 PMCID: PMC9787424 DOI: 10.1111/ecc.13705] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/11/2021] [Revised: 09/02/2022] [Accepted: 09/07/2022] [Indexed: 12/30/2022]
Abstract
OBJECTIVES The objectives were to describe patients' experiences of cancer care in Switzerland and explore the variation of these experiences by type of cancer. METHODS The Swiss Cancer Patient Experiences (SCAPE) study was a cross-sectional, multicentre survey conducted in 2018. Adult patients (n = 7145) with breast, prostate, lung, colorectal, skin or haematological cancer from four large hospitals in French-speaking Switzerland were invited to complete a survey. Logistic regressions were used to assess whether experiences varied according to cancer type, adjusting for confounders. RESULTS Of the 3121 persons who returned the survey (44% response rate), 2755 reporting an eligible cancer were included in the analyses. Participants' average score for overall care was 8.5 out of a maximum score of 10. Higher rates of positive experiences were found for nurse consultations (94%), diagnostic tests (85%) and inpatient care (82%). Lower positive responses were reported for support for people with cancer (70%), treatment decisions (66%), diagnosis (65%) and home care (55%). We observed non-systematic differences in experiences of care by cancer type. CONCLUSIONS This large study identified that cancer patient experiences can be improved in relation to communication, information and supportive care aspects. Improvement efforts should target these areas of care to enhance responsiveness of cancer care.
Collapse
Affiliation(s)
- Chantal Arditi
- Department of Epidemiology and Health Systems, Center for Primary Care and Public Health (Unisanté)University of LausanneLausanneSwitzerland
| | - Manuela Eicher
- Institute of Higher Education and Research in Healthcare (IUFRS), Faculty of Biology and MedicineUniversity of LausanneLausanneSwitzerland,Department of OncologyLausanne University Hospital (CHUV)LausanneSwitzerland
| | - Sara Colomer‐Lahiguera
- Institute of Higher Education and Research in Healthcare (IUFRS), Faculty of Biology and MedicineUniversity of LausanneLausanneSwitzerland
| | - Christine Bienvenu
- Department of Epidemiology and Health Systems, Center for Primary Care and Public Health (Unisanté)University of LausanneLausanneSwitzerland
| | - Sandro Anchisi
- Oncology ServiceHôpital du Valais ‐ Hospital Center of Valais Romand (CHVR)SionSwitzerland
| | - Daniel Betticher
- Department of OncologyHFR Fribourg – Cantonal HospitalFribourgSwitzerland
| | | | - Michel Duchosal
- Department of OncologyLausanne University Hospital (CHUV)LausanneSwitzerland
| | - Solange Peters
- Department of OncologyLausanne University Hospital (CHUV)LausanneSwitzerland
| | - Isabelle Peytremann‐Bridevaux
- Department of Epidemiology and Health Systems, Center for Primary Care and Public Health (Unisanté)University of LausanneLausanneSwitzerland
| |
Collapse
|
2
|
Bai JF, Majjigapu SR, Sordat B, Poty S, Vogel P, Elías-Rodríguez P, Moreno-Vargas AJ, Carmona AT, Caffa I, Ghanem M, Khalifa A, Monacelli F, Cea M, Robina I, Gajate C, Mollinedo F, Bellotti A, Nahimana A, Duchosal M, Nencioni A. Identification of new FK866 analogues with potent anticancer activity against pancreatic cancer. Eur J Med Chem 2022; 239:114504. [PMID: 35724566 DOI: 10.1016/j.ejmech.2022.114504] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2022] [Revised: 05/25/2022] [Accepted: 05/27/2022] [Indexed: 11/22/2022]
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal diseases for which chemotherapy has not been very successful yet. FK866 ((E)-N-(4-(1-benzoylpiperidin-4-yl)butyl)-3-(pyridin-3-yl)acrylamide) is a well-known NAMPT (nicotinamide phosphoribosyltransferase) inhibitor with anti-cancer activities, but it failed in phase II clinical trials. We found that FK866 shows anti-proliferative activity in three PDAC cell lines, as well as in Jurkat T-cell leukemia cells. More than 50 FK866 analogues were synthesized that introduce substituents on the phenyl ring of the piperidine benzamide group of FK866 and exchange its buta-1,4-diyl tether for 1-oxyprop-3-yl, (E)-but-2-en-1,4-diyl and 2- and 3-carbon tethers. The pyridin-3-yl moiety of FK866 was exchanged for chlorinated and fluorinated analogues and for pyrazin-2-yl and pyridazin-4-yl groups. Several compounds showed low nanomolar or sub-nanomolar cell growth inhibitory activity. Our best cell anti-proliferative compounds were the 2,4,6-trimethoxybenzamide analogue of FK866 ((E)-N-(4-(1-(2,4,6-trimethoxybenzoyl)piperidin-4-yl)butyl)-3-(pyridin-3-yl)acrylamide) (9), the 2,6-dimethoxybenzamide (8) and 2-methoxybenzamide (4), which exhibited an IC50 of 0.16 nM, 0.004 nM and 0.08 nM toward PDAC cells, respectively.
Collapse
Affiliation(s)
- Jian-Fei Bai
- Laboratory of Glycochemistry and Asymmetric Synthesis, Swiss Institute of Technology (EPFL), 1015, Lausanne, Switzerland
| | - Somi Reddy Majjigapu
- Laboratory of Glycochemistry and Asymmetric Synthesis, Swiss Institute of Technology (EPFL), 1015, Lausanne, Switzerland
| | - Bernard Sordat
- Laboratory of Glycochemistry and Asymmetric Synthesis, Swiss Institute of Technology (EPFL), 1015, Lausanne, Switzerland
| | - Sophie Poty
- Laboratory of Glycochemistry and Asymmetric Synthesis, Swiss Institute of Technology (EPFL), 1015, Lausanne, Switzerland
| | - Pierre Vogel
- Laboratory of Glycochemistry and Asymmetric Synthesis, Swiss Institute of Technology (EPFL), 1015, Lausanne, Switzerland
| | - Pilar Elías-Rodríguez
- Departamento de Química Orgánica, Facultad de Química, Universidad de Sevilla, Sevilla, 41012, Spain
| | - Antonio J Moreno-Vargas
- Departamento de Química Orgánica, Facultad de Química, Universidad de Sevilla, Sevilla, 41012, Spain
| | - Ana T Carmona
- Departamento de Química Orgánica, Facultad de Química, Universidad de Sevilla, Sevilla, 41012, Spain
| | - Irene Caffa
- Department of Internal Medicine and Medical Specialties, University of Genoa, 16132, Genoa, Italy
| | - Moustafa Ghanem
- Department of Internal Medicine and Medical Specialties, University of Genoa, 16132, Genoa, Italy
| | - Amr Khalifa
- Department of Internal Medicine and Medical Specialties, University of Genoa, 16132, Genoa, Italy; Ospedale Policlinico San Martino IRCCS, Genoa, Italy
| | - Fiammetta Monacelli
- Department of Internal Medicine and Medical Specialties, University of Genoa, 16132, Genoa, Italy; Ospedale Policlinico San Martino IRCCS, Genoa, Italy
| | - Michele Cea
- Department of Internal Medicine and Medical Specialties, University of Genoa, 16132, Genoa, Italy; Ospedale Policlinico San Martino IRCCS, Genoa, Italy
| | - Inmaculada Robina
- Departamento de Química Orgánica, Facultad de Química, Universidad de Sevilla, Sevilla, 41012, Spain
| | - Consuelo Gajate
- Laboratory of Cell Death and Cancer Therapy, Department of Molecular Biomedicine Centro de Investigaciones Biológicas Margarita Salas, Consejo Superior de Investigaciones Científicas (CSIC), Madrid, Spain
| | - Faustino Mollinedo
- Laboratory of Cell Death and Cancer Therapy, Department of Molecular Biomedicine Centro de Investigaciones Biológicas Margarita Salas, Consejo Superior de Investigaciones Científicas (CSIC), Madrid, Spain
| | - Axel Bellotti
- Central Laboratory of Hematology, Medical Laboratory and Pathology Department, Lausanne University Hospital, 1011, Lausanne, Switzerland
| | - Aimable Nahimana
- Central Laboratory of Hematology, Medical Laboratory and Pathology Department, Lausanne University Hospital, 1011, Lausanne, Switzerland
| | - Michel Duchosal
- Central Laboratory of Hematology, Medical Laboratory and Pathology Department, Lausanne University Hospital, 1011, Lausanne, Switzerland; Service of Hematology, Oncology Department, Lausanne University Hospital, 1011, Lausanne, Switzerland
| | - Alessio Nencioni
- Department of Internal Medicine and Medical Specialties, University of Genoa, 16132, Genoa, Italy; Ospedale Policlinico San Martino IRCCS, Genoa, Italy.
| |
Collapse
|
3
|
Ghanem M, Khalifa A, Caffa I, Nahimana A, Duchosal M, Rio AD, Bruzzone S, Piancente F, Nencioni A. Abstract 6254: Identification of nicotinic acid phosphoribosyltransferase inhibitors with anticancer properties by in silico drug design. Cancer Res 2022. [DOI: 10.1158/1538-7445.am2022-6254] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Cancer cells rely heavily on sustained NAD levels to support their survival and proliferation. Thus, depleting NAD levels in tumor cells through interference with their NAD-biosynthetic machinery has been proposed as a promising anticancer strategy. Several pathways contribute to NAD production in mammals, such as the de novo and the Preiss-Handler (PH) pathways, which generate NAD from tryptophan and from nicotinic acid, respectively. In addition, the NAD salvage pathway, which utilizes nicotinamide as a substrate, is also a major NAD-producing route and its rate-limiting enzyme, nicotinamide phosphoribosyltransferase (NAMPT), is commonly overexpressed in a multitude of human cancers. Over the past two decades, several potent NAMPT inhibitors have been developed, such as FK866. However, their clinical efficacy has proven limited, suggesting that the other NAD-producing routes are frequently also active in cancer cells and are responsible for causing resistance to NAMPT inhibitors. Recently, we have shown nicotinic acid phosphoribosyl transferase (NAPRT), the key enzyme in the PH pathway, to play an important role in NAD metabolism in cancer cells. We demonstrated that NAPRT is amplified and overexpressed in several types of solid tumors and that its expression is a critical determinant of cancer cell susceptibility to NAMPT inhibitors. Although several NAPRT inhibitors have been reported, including 2-hydroxy nicotinic acid (2-HNA), their low potency and/or poor solubility limit their clinical applicability. To identify new NAPRT inhibitors with enhanced pharmacological profiles, we performed a high-throughput molecular docking screen, taking advantage of the availability of NAPRT crystal structure. The first 500 hits were visually inspected to prioritize compounds that reproduced, at least in part, the putative binding mode of known substrates and inhibitors and complied with simple physicochemical rules such as Lipinski’s rule of five. In addition, several 2-HNA analogs were selected. Altogether, this led to a final list of 50 compounds that were tested in vitro. We show that four compounds from this list were able to sensitize NAPRT-overexpressing ovarian cancer cells to FK866, resulting in a more significant reduction in intracellular NAD levels, as well as in a much more pronounced cytotoxicity as compared to FK866 alone. The inhibitory constant (Ki) of the new NAPRT inhibitors was found to be in the micromolar range. In conclusion, in silico molecular docking screens are a promising approach to identify new NAPRT inhibitors with anticancer effects.
Citation Format: Moustafa Ghanem, Amr Khalifa, Irene Caffa, Aimable Nahimana, Michel Duchosal, Alberto Del Rio, Santina Bruzzone, Francesco Piancente, Alessio Nencioni. Identification of nicotinic acid phosphoribosyltransferase inhibitors with anticancer properties by in silico drug design [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 6254.
Collapse
Affiliation(s)
| | | | | | - Aimable Nahimana
- 2CHUV-Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
| | - Michel Duchosal
- 3CHUV- Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
| | | | | | | | | |
Collapse
|
4
|
Bargetzi M, Baumann R, Cogliatti S, Dietrich PY, Duchosal M, Goede J, Hitz F, Konermann C, Lohri A, Mey U, Novak U, Papachristofilou A, Stenner F, Taverna C, Zander T, Renner C. Diagnosis and treatment of follicular lymphoma: an update. Swiss Med Wkly 2018; 148:w14635. [PMID: 30044476 DOI: 10.4414/smw.2018.14635] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022] Open
Abstract
Over the last few years, there have been many changes in the management of patients with follicular lymphoma, resulting in improvements in progression-free survival and quality of life. In addition to established regimens such as radiotherapy and immunochemotherapy, new treatment options are on the horizon. Furthermore, even the use of established chemotherapy agents has evolved, with new combinations moving to the forefront of the current treatment strategy. Nevertheless, there remains an unmet need for patients who have early relapses, those who are not responsive to anti-CD20 treatment regimens and for those in whom minimal residual disease persists even after immunochemotherapy. This review provides a summary of current developments in the diagnosis, treatment and management of follicular lymphoma, focusing on the clinical issues from a Swiss perspective.
Collapse
Affiliation(s)
| | | | | | | | - Michel Duchosal
- Service and Central Laboratory of Hematology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
| | - Jeroen Goede
- Oncology and Haematology, Kantonsspital Winterthur, Switzerland
| | | | | | - Andreas Lohri
- Oncology-Haematology, Kantonsspital Baselland, Liestal, Switzerland
| | - Ulrich Mey
- Oncology and Haematology, Kantonsspital Graubuenden, Chur, Switzerland
| | - Urban Novak
- President of the SAKK Project Group Lymphoma, Medical Oncology, Inselspital, University Hospital and University of Bern, Bern, Switzerland
| | | | - Frank Stenner
- Department of Oncology, Universitätsspital Basel, Switzerland
| | | | - Thilo Zander
- Department of Oncology, Luzerner Kantonsspital, Luzern, Switzerland
| | | |
Collapse
|
5
|
Cagnetta A, Soncini D, Orecchioni S, Talarico G, Minetto P, Guolo F, Retali V, Colombo N, Carminati E, Clavio M, Miglino M, Bergamaschi M, Nahimana A, Duchosal M, Todoerti K, Neri A, Passalacqua M, Bruzzone S, Nencioni A, Bertolini F, Gobbi M, Lemoli RM, Cea M. Depletion of SIRT6 enzymatic activity increases acute myeloid leukemia cells' vulnerability to DNA-damaging agents. Haematologica 2017; 103:80-90. [PMID: 29025907 PMCID: PMC5777193 DOI: 10.3324/haematol.2017.176248] [Citation(s) in RCA: 38] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/11/2017] [Accepted: 10/09/2017] [Indexed: 12/18/2022] Open
Abstract
Genomic instability plays a pathological role in various malignancies, including acute myeloid leukemia (AML), and thus represents a potential therapeutic target. Recent studies demonstrate that SIRT6, a NAD+-dependent nuclear deacetylase, functions as genome-guardian by preserving DNA integrity in different tumor cells. Here, we demonstrate that also CD34+ blasts from AML patients show ongoing DNA damage and SIRT6 overexpression. Indeed, we identified a poor-prognostic subset of patients, with widespread instability, which relies on SIRT6 to compensate for DNA-replication stress. As a result, SIRT6 depletion compromises the ability of leukemia cells to repair DNA double-strand breaks that, in turn, increases their sensitivity to daunorubicin and Ara-C, both in vitro and in vivo In contrast, low SIRT6 levels observed in normal CD34+ hematopoietic progenitors explain their weaker sensitivity to genotoxic stress. Intriguingly, we have identified DNA-PKcs and CtIP deacetylation as crucial for SIRT6-mediated DNA repair. Together, our data suggest that inactivation of SIRT6 in leukemia cells leads to disruption of DNA-repair mechanisms, genomic instability and aggressive AML. This synthetic lethal approach, enhancing DNA damage while concomitantly blocking repair responses, provides the rationale for the clinical evaluation of SIRT6 modulators in the treatment of leukemia.
Collapse
Affiliation(s)
- Antonia Cagnetta
- Chair of Hematology, Department of Internal Medicine (DiMI), University of Genova, Italy.,Hematology Unit, Policlinico San Martino, Genova, Italy
| | - Debora Soncini
- Chair of Hematology, Department of Internal Medicine (DiMI), University of Genova, Italy
| | | | | | - Paola Minetto
- Chair of Hematology, Department of Internal Medicine (DiMI), University of Genova, Italy
| | - Fabio Guolo
- Chair of Hematology, Department of Internal Medicine (DiMI), University of Genova, Italy
| | - Veronica Retali
- Chair of Hematology, Department of Internal Medicine (DiMI), University of Genova, Italy.,Hematology Unit, Policlinico San Martino, Genova, Italy
| | - Nicoletta Colombo
- Chair of Hematology, Department of Internal Medicine (DiMI), University of Genova, Italy
| | - Enrico Carminati
- Chair of Hematology, Department of Internal Medicine (DiMI), University of Genova, Italy
| | - Marino Clavio
- Chair of Hematology, Department of Internal Medicine (DiMI), University of Genova, Italy.,Hematology Unit, Policlinico San Martino, Genova, Italy
| | - Maurizio Miglino
- Chair of Hematology, Department of Internal Medicine (DiMI), University of Genova, Italy.,Hematology Unit, Policlinico San Martino, Genova, Italy
| | - Micaela Bergamaschi
- Chair of Hematology, Department of Internal Medicine (DiMI), University of Genova, Italy
| | - Aimable Nahimana
- Service and Central Laboratory of Hematology, University Hospital of Lausanne, Switzerland
| | - Michel Duchosal
- Service and Central Laboratory of Hematology, University Hospital of Lausanne, Switzerland
| | - Katia Todoerti
- Laboratory of Pre-Clinical and Translational Research, IRCCS-CROB, Referral Cancer Center of Basilicata, Rionero in Vulture, Potenza, Italy
| | - Antonino Neri
- Department of Oncology and Hemato-Oncology, University of Milan, Italy.,Hematology Unit, Fondazione Cà Granda, Ospedale Maggiore Policlinico, Milan, Italy
| | - Mario Passalacqua
- Department of Experimental Medicine, University of Genova, Italy and
| | - Santina Bruzzone
- Department of Experimental Medicine, University of Genova, Italy and
| | - Alessio Nencioni
- Hematology Unit, Policlinico San Martino, Genova, Italy.,Department of Internal Medicine, University of Genova, Italy
| | | | - Marco Gobbi
- Chair of Hematology, Department of Internal Medicine (DiMI), University of Genova, Italy.,Hematology Unit, Policlinico San Martino, Genova, Italy
| | - Roberto M Lemoli
- Chair of Hematology, Department of Internal Medicine (DiMI), University of Genova, Italy.,Hematology Unit, Policlinico San Martino, Genova, Italy
| | - Michele Cea
- Chair of Hematology, Department of Internal Medicine (DiMI), University of Genova, Italy .,Hematology Unit, Policlinico San Martino, Genova, Italy
| |
Collapse
|
6
|
Noetzli J, Gavillet M, Masouridi‐Levrat S, Duchosal M, Spertini O. T315I clone selection in a Ph+ all patient under low-dose ponatinib maintenance. Clin Case Rep 2017; 5:1320-1322. [PMID: 28781850 PMCID: PMC5538043 DOI: 10.1002/ccr3.1032] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/14/2016] [Revised: 03/27/2017] [Accepted: 04/28/2017] [Indexed: 01/30/2023] Open
Abstract
We report here the clinical course of a Ph+ ALL patient who was treated with ponatinib 15 mg/day, as maintenance therapy, and developed a BCR‐ABL T315I mutation leading to ALL relapse. This clonal evolution was reversed, without adverse effects, by increasing ponatinib to 45 mg/day. To our knowledge, we have been confronted with the first clinical case of a T315I clonal selection of ALL caused by subeffective therapeutic level of the drug. This single patient experience highlights the risk of T315I clone selection in Ph+ ALL treated with reduced dose ponatinib.
Collapse
Affiliation(s)
- Jasmine Noetzli
- Service and Central Laboratory of HematologyUniversity Hospital of Lausanne (CHUV)LausanneSwitzerland
| | - Mathilde Gavillet
- Service and Central Laboratory of HematologyUniversity Hospital of Lausanne (CHUV)LausanneSwitzerland
| | | | - Michel Duchosal
- Service and Central Laboratory of HematologyUniversity Hospital of Lausanne (CHUV)LausanneSwitzerland
| | - Olivier Spertini
- Service and Central Laboratory of HematologyUniversity Hospital of Lausanne (CHUV)LausanneSwitzerland
| |
Collapse
|
7
|
Piacente F, Caffa I, Ravera S, Sociali G, Passalacqua M, Vellone VG, Becherini P, Reverberi D, Monacelli F, Ballestrero A, Odetti P, Cagnetta A, Cea M, Nahimana A, Duchosal M, Bruzzone S, Nencioni A. Nicotinic Acid Phosphoribosyltransferase Regulates Cancer Cell Metabolism, Susceptibility to NAMPT Inhibitors, and DNA Repair. Cancer Res 2017; 77:3857-3869. [PMID: 28507103 DOI: 10.1158/0008-5472.can-16-3079] [Citation(s) in RCA: 70] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/17/2016] [Revised: 04/06/2017] [Accepted: 05/12/2017] [Indexed: 11/16/2022]
Abstract
In the last decade, substantial efforts have been made to identify NAD+ biosynthesis inhibitors, specifically against nicotinamide phosphoribosyltransferase (NAMPT), as preclinical studies indicate their potential efficacy as cancer drugs. However, the clinical activity of NAMPT inhibitors has proven limited, suggesting that alternative NAD+ production routes exploited by tumors confer resistance. Here, we show the gene encoding nicotinic acid phosphoribosyltransferase (NAPRT), a second NAD+-producing enzyme, is amplified and overexpressed in a subset of common types of cancer, including ovarian cancer, where NAPRT expression correlates with a BRCAness gene expression signature. Both NAPRT and NAMPT increased intracellular NAD+ levels. NAPRT silencing reduced energy status, protein synthesis, and cell size in ovarian and pancreatic cancer cells. NAPRT silencing sensitized cells to NAMPT inhibitors both in vitro and in vivo; similar results were obtained with the NAPRT inhibitor 2-hydroxynicotinic acid. Reducing NAPRT levels in a BRCA2-deficient cancer cell line exacerbated DNA damage in response to chemotherapeutics. In conclusion, NAPRT-dependent NAD+ biosynthesis contributes to cell metabolism and to the DNA repair process in a subset of tumors. This knowledge could be used to increase the efficacy of NAMPT inhibitors and chemotherapy. Cancer Res; 77(14); 3857-69. ©2017 AACR.
Collapse
Affiliation(s)
- Francesco Piacente
- Department of Internal Medicine and Medical Specialties, University of Genoa, Genoa, Italy
| | - Irene Caffa
- Department of Internal Medicine and Medical Specialties, University of Genoa, Genoa, Italy
| | - Silvia Ravera
- Department of Pharmacy, Biochemistry Lab, Genoa, Italy
| | - Giovanna Sociali
- Department of Experimental Medicine, University of Genoa, Genoa, Italy
| | - Mario Passalacqua
- Department of Experimental Medicine, University of Genoa, Genoa, Italy
| | - Valerio G Vellone
- Department of Integrated, Surgical and Diagnostic Sciences, University of Genoa, Genoa, Italy.,Ospedale Policlinico San Martino, I.R.C.C.S. per l'Oncologia, Genoa, Italy
| | - Pamela Becherini
- Department of Internal Medicine and Medical Specialties, University of Genoa, Genoa, Italy
| | - Daniele Reverberi
- Ospedale Policlinico San Martino, I.R.C.C.S. per l'Oncologia, Genoa, Italy
| | - Fiammetta Monacelli
- Department of Internal Medicine and Medical Specialties, University of Genoa, Genoa, Italy
| | - Alberto Ballestrero
- Department of Internal Medicine and Medical Specialties, University of Genoa, Genoa, Italy.,Ospedale Policlinico San Martino, I.R.C.C.S. per l'Oncologia, Genoa, Italy
| | - Patrizio Odetti
- Department of Internal Medicine and Medical Specialties, University of Genoa, Genoa, Italy.,Ospedale Policlinico San Martino, I.R.C.C.S. per l'Oncologia, Genoa, Italy
| | - Antonia Cagnetta
- Department of Internal Medicine and Medical Specialties, University of Genoa, Genoa, Italy.,Ospedale Policlinico San Martino, I.R.C.C.S. per l'Oncologia, Genoa, Italy
| | - Michele Cea
- Department of Internal Medicine and Medical Specialties, University of Genoa, Genoa, Italy.,Ospedale Policlinico San Martino, I.R.C.C.S. per l'Oncologia, Genoa, Italy
| | - Aimable Nahimana
- Service and Central Laboratory of Hematology, University Hospital of Lausanne, Lausanne, Switzerland
| | - Michel Duchosal
- Service and Central Laboratory of Hematology, University Hospital of Lausanne, Lausanne, Switzerland
| | - Santina Bruzzone
- Department of Experimental Medicine, University of Genoa, Genoa, Italy
| | - Alessio Nencioni
- Department of Internal Medicine and Medical Specialties, University of Genoa, Genoa, Italy. .,Ospedale Policlinico San Martino, I.R.C.C.S. per l'Oncologia, Genoa, Italy
| |
Collapse
|
8
|
Gotta V, Widmer N, Decosterd L, Chalandon Y, Heim D, Benz R, Gregor M, Leoncini-Franscini L, Baerlocher G, Duchosal M, Csajka C, Buclin T. OC014—Clinical Usefulness Of Therapeutic Concentration Monitoring For Imatinib Dosage Individualization: Results From The Randomized Controlled I-Come Trial. Clin Ther 2013. [DOI: 10.1016/j.clinthera.2013.07.013] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
9
|
Passweg J, Baldomero H, Stern M, Bargetzi M, Ghielmini M, Leibundgut K, Duchosal M, Hess U, Seger R, Buhrfeind E, Schanz U, Gratwohl A. Hematopoietic stem cell transplantation in Switzerland: a comprehensive quality control report on centre effect. Swiss Med Wkly 2010; 140:326-34. [PMID: 20349362 DOI: 10.4414/smw.2010.12978] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
Abstract
QUESTIONS UNDER STUDY / PRINCIPLES Interest groups advocate centre-specific outcome data as a useful tool for patients in choosing a hospital for their treatment and for decision-making by politicians and the insurance industry. Haematopoietic stem cell transplantation (HSCT) requires significant infrastructure and represents a cost-intensive procedure. It therefore qualifies as a prime target for such a policy. METHODS We made use of the comprehensive database of the Swiss Blood Stem Cells Transplant Group (SBST) to evaluate potential use of mortality rates. Nine institutions reported a total of 4717 HSCT - 1427 allogeneic (30.3%), 3290 autologous (69.7%) - in 3808 patients between the years 1997 and 2008. Data were analysed for survival- and transplantation-related mortality (TRM) at day 100 and at 5 years. RESULTS The data showed marked and significant differences between centres in unadjusted analyses. These differences were absent or marginal when the results were adjusted for disease, year of transplant and the EBMT risk score (a score incorporating patient age, disease stage, time interval between diagnosis and transplantation, and, for allogeneic transplants, donor type and donor-recipient gender combination) in a multivariable analysis. CONCLUSIONS These data indicate comparable quality among centres in Switzerland. They show that comparison of crude centre-specific outcome data without adjustment for the patient mix may be misleading. Mandatory data collection and systematic review of all cases within a comprehensive quality management system might, in contrast, serve as a model to ascertain the quality of other cost-intensive therapies in Switzerland.
Collapse
Affiliation(s)
- Jakob Passweg
- Haematology, University Hospital, Geneva (HUG), Switzerland.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Schurmans S, Merino J, Qin HY, Kramar G, Duchosal M, Skalli O, Benzonana G, Gabbiani G, Lambert PH. Autoimmune syndrome after neonatal induction of tolerance to alloantigens: analysis of the specificity and of the cellular and genetic origin of autoantibodies. Autoimmunity 1991; 9:283-91. [PMID: 1720028 DOI: 10.3109/08916939108997130] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
BALB/c mice neonatally injected with 10(8) semiallogeneic (C57BL/6 x BALB/c)F1 spleen cells become tolerant to the H-2b alloantigens, but also develop a wide range of autoimmune manifestations characteristic of systemic lupus erythematosus (SLE). Indeed, in these mice, the presence of a hypergammaglobulinaemia, autoantibodies--including anti-ssDNA, anti-platelet, thymocytotoxic and rheumatoid factor antibodies--circulating immune complexes, cryoglobulins as well as renal glomerular deposition of immunoglobulins have been observed. In this study, we have shown that the allogenic effect and B cell chimaerism which characterize these F1 cell-injected mice is associated with the expression of a large spectrum of autoantibodies, including anti-ssDNA and anti-cytoskeleton antibodies, and that these autoantibodies are not multispecific. We took advantage of the fact that, in this model, autoantibodies are exclusively produced by F1 donor B cells to inject newborn BALB/c mice with F1 Xid spleen cells lacking the CD5+ B cell subset. Injection of 2 x 10(8) F1 Xid spleen cells triggers the production of anti-ssDNA as well as anti-BrMRBC antibodies, and these mice developed tissue lesions. Finally, analysis of the VH gene family expressed by monoclonal autoantibodies derived from F1 cell-injected mice showed that they used the 2 largest families J558 and 7183. These results suggest that the allogenic effect and B cell chimerism which characterize the neonatal induction of tolerance to MHC alloantigens is associated with the selective triggering of autoreactive B cells producing monospecific IgG autoantibodies. They also imply that upon stimulation by persisting alloreactive CD4+ T cells, either CD5- B cells are able to produce autoantibodies or autoantibody-producing CD5+ B cells can differentiate from Xid spleen cells.
Collapse
Affiliation(s)
- S Schurmans
- WHO Immunology Research and Training Center, Geneva, Switzerland
| | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Duchosal M. [Interstitial nephritis as a result of analgesic abuse]. Rev Med Suisse Romande 1984; 104:323-7. [PMID: 6740054] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
|